Sodium‐glucose co‐transporter‐2 inhibitors and major adverse limb events: A trial‐level meta‐analysis including 51 713 individuals

SGLT-2 inhibitors are not associated with increased risks of amputation operations even among various high-risk subgroups, including patients with PAD. The amputation events primarily arise from critical limb ischaemia and infection instead of acute limb ischaemia. A multi-centre study focused on major adverse limb events with a longer follow-up is needed to confirm these results and provide guidelines for clinical practice.